Our study found an overall neonatal hyperbilirubinemia incidence of 10% (50/500), with rates of 2.98%, 8.98%, and 18.18% in the low-, moderate-, and high-dose oxytocin groups, respectively, indicating a significant association between high-dose oxytocin exposure and increased risk of neonatal hyperbilirubinemia. The gene discussed is OXT; the disease is Hyperbilirubinemia.